

04/07/00

09544683-040700

04-10-00

A

Please type a plus sign (+) inside this box → ☐

Approved for use through 09/30/2000. OMB 0651-0032  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 99471 US

First Inventor or Application Identifier: Antonius A.C. JACOBS et al.

Title: CAMPYLOBACTER VACCINE

Express Mail Label No. EL087179852 US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

## ADDRESS TO:

 Assistant Commissioner for Patents  
 Box Patent Application  
 Washington, DC 20231

 1. ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
 (Submit an original and a duplicate for fee processing)

 2. ☒ Specification [Total Pages 19]

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

 3. ☒ Drawing(s) (35 U.S.C. 119) [Total Sheets 3]

4. Oath or Declaration [Total Pages 2]

- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
 (for continuation/divisional with Box 16 completed)
- i. ☐ DELETION OF INVENTOR(S)  
 Signed statement attached deleting  
 inventor(s) named in the prior application,  
 see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

\* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY  
 FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27) EXCEPT  
 IF ONE FILED BY A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

5. ☐ Microfiche Computer Program (Appendix)
 6. Nucleotide and/or Amino Acid Sequence Submission  
 (if applicable, all necessary)

- a. ☒ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

7. ☒ Assignment Papers (cover sheet & document(s))
 8. ☐ 37 C.F.R. § 3.79(b) Statement of Power of Attorney  
 (when there is an assignee)
9. ☐ English Translation Document (if applicable)
 10. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
11. ☒ Preliminary Amendment
 12. ☒ Return Receipt Postcard (MPEP 503)  
 (Should be specifically itemized)

 13. ☐ \* Small Entity Statement(s) filed in prior application.  
 (PTO/SB-05-12) Status still proper and desired

 14. ☐ Certified Copy of Priority Document(s)  
 (if foreign priority is claimed)
15. ☐ Other:
 16. IF A CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:  
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. \_\_\_\_\_  
 Prior application information: Examiner \_\_\_\_\_ Group / Art Unit: \_\_\_\_\_

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied  
 under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by  
 reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

or ☐ Correspondence address below
 Name: William M. Blackstone  
 Akzo Nobel Patent Department  
 Address: 1300 Piccard Drive Suite 206

City: Rockville

State: MD

Zip Code: 20850

Country: US

Telephone: (301)948-7400

Fax: (301)948-9751

Name (Print/Type) William M. Blackstone

Registration No. (Attorney/Agent) 29,772

Signature



Date

4/7/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any  
 comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,  
 Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,  
 Box Patent Application, Washington, DC 20231.

 09544683  
 04/07/00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of:

Antonius A. C. JACOBS, Johannes F. van den BOSCH,  
Petrus J. M. NUIJTEN

Serial Number: To be assigned Group Art Unit: To be assigned

Filed: Concurrently herewith Examiner: To be assigned

For: CAMPYLOBACTER VACCINE

Corresponding to: EP 99201086.8, filed April 9, 1999

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

April 7, 2000

Sir:

Prior to the calculation of the fee in the above-identified application, please make the following amendments:

IN THE SPECIFICATION:

Page 1, between lines 1 and 3, please insert

-- BACKGROUND OF THE INVENTION

1. Field of the Invention --;

before line 6, please insert -- 2. Description of  
Related Art --.

Page 2, before line 43, please insert -- SUMMARY OF  
THE INVENTION --.

Page 3, between lines 7 and 9, please insert

-- BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Western blot comprising total antigen of  
wild type *Campylobacter* strain 81116 (left), and

Western blot comprising antigen of flagellates

*Campylobacter* strain 81116-2R. Lanes 1 and 7, and

lanes 2 and 8, and lanes 3 and 9 were incubated with

09:44:53.040700

002040-8894-56

type *Campylobacter* strain 81116 respectively. Lanes 4 and 10, lanes 5 and 11, and lanes 6 and 12 were incubated with 20, 200 or 400 times diluted antiserum against flagellaless *Campylobacter* strain 81116-2R respectively.

Figure 2. 2-D gel of total antigen of wild type *Campylobacter* strain 81116.

Figure 3a. Western blot of the 2-D gel incubated with antiserum against flagellaless *Campylobacter* strain 81116-2R. The 60 kD protein is indicated by arrow 1, the 13 kD protein by arrow 2.

Figure 3b. Western blot of the 2-D gel incubated with antiserum against wild-type *Campylobacter* strain 81116.

DESCRIPTION OF PREFERRED EMBODIMENT --;

Page 3, line 9, please delete "Thus one" and insert  
-- One --.

Please delete page 16 in its entirety.

IN THE CLAIMS:

1. (amended) [Vaccine] A vaccine for the prevention of *Campylobacter* colonisation in animals, characterised in that said vaccine comprises antiserum raised against a flagellaless *Campylobacter* strain .

2. (amended) [Vaccine] A vaccine according to claim 1, characterised in that the flagellaless *Campylobacter* strain is *Campylobacter jejuni*.

3. (amended) [Vaccine] A vaccine according to claim 2, characterised in that the flagellaless *Campylobacter jejuni* strain is strain R2.

4. (amended) [Antigenic] An antigenic protein of *Campylobacter* having a molecular weight of 97 kD (+/-5kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.

5. (amended) [Antigenic] An antigenic protein of *Campylobacter* having a molecular weight of 60 kD (+/-5kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies

against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.

6. (amended) [Antigenic] An antigenic protein of *Campylobacter* having a molecular weight of 13 kD (+/-3kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is visible after incubation of said blot with antibodies against wild *Campylobacter jejuni*.

7. (amended) [Antigenic] An antigenic protein according to claim 4 [,5 or 6] for use in a vaccine.

8. (amended) Use of antigenic protein as defined in claim 4 [,5 or 6] for the manufacturing of a pharmaceutical composition for combating *Campylobacter jejuni* colonisation.

9. (amended) [Vaccine] A vaccine for the prevention of *Campylobacter jejuni* colonisation in poultry, characterised in that said vaccine comprises antibodies against the antigenic protein according to claim 4 [,5 or 6].

10. (amended) [Vaccine] A vaccine for the prevention of *Campylobacter jejuni* colonisation in poultry, characterised in

that said vaccine comprises an antigenic protein according to claim 4 [, 5 or 6].

11. (amended) Use of antibodies against a flagellaless *Campylobacter* strain, or against the antigenic protein of claim 4 [, 5 or 6] for the preparation of a vaccine against *Campylobacter* colonisation in animals.

12. (amended) [Method] A method for the preparation of a vaccine according to [any of the claims 1-3 or 9] claim 1, characterised in that said method comprises raising antiserum against antigenic material of a flagellaless *Campylobacter* strain in a host animal followed by isolating the antiserum of the host animal.

13. (amended) [Method] A method for the preparation of a vaccine according to claim 9, characterised in that said method comprises growing antibody producing cells and harvesting the antibodies.

14. (amended) [Method] A method for the preparation of a vaccine according to claim 10, characterised in that said method comprises admixing a protein according to [any of the claims 4-6] claim 4 and a pharmaceutically acceptable carrier.

#### REMARKS

Claims 1 - 14 are amended. It is believed that claims 1 - 14 recite a patentable improvement in the art. Favorable

action is solicited. In the event any fees are required with  
this paper, please charge our Deposit Account No. 02-2334.

Respectfully submitted,



William M. Blackstone  
Attorney for Applicants  
Registration No. 29,772

Attorney Docket NO.99471 US  
AKZO NOBEL PATENT DEPARTMENT  
1300 Piccard Drive, Suite 206  
Rockville, Maryland 20850-4373  
Tel: (301) 948-7400  
Fax: (301) 948-9751

GRM:plb

40jacobs.pream

002070-889450

## *Campylobacter* vaccine

The present invention relates to vaccines against *Campylobacter* colonisation, to the use of *Campylobacter* proteins and anti-*Campylobacter* antibodies for the preparation of such vaccines and to methods for the preparation of such vaccines.

Bacteria of the genus *Campylobacter* are Gram-negative spiral shaped pathogenic bacteria, with a high motility and carrying a flagellum at one or both poles of the cell. Several *Campylobacter* species have been found. *Campylobacter jejuni* is very often found in poultry. Frequently *Campylobacter coli* and (to a lesser extent) the recently found *Campylobacter hyoilei* are found in pigs.

Of these, *Campylobacter jejuni* is the most frequently isolated *Campylobacter* species in association with human diarrhoea. It is becoming more and more evident that the number of *Campylobacter* infections in humans exceeds the number of Salmonella infections. (Griffiths et al., Journ. of Applied Bacteriology 1990, 69: 281-301, Walker et al., Microbiological reviews 1986, 50: 81-94, Butzler, J-P., ISBN 0-8493-5446-3, RIVM Report No. 216852002, Bilthoven, the Netherlands). It is difficult to avoid infection in humans with *Campylobacter* since, first of all, *Campylobacter* is a food borne zoonotic bacterium for which many animals, both wild and domestic, healthy or sick serve as a reservoir. In addition the bacterium has many different routes of transmission. Bacteria can survive in a dormant coccal form for several weeks on e.g. the surface of carcasses and in water. The bacterium can therefore easily be transmitted to man through direct contact with animals or by means of contaminated water or food, e.g. milk or meat. *C. jejuni* is present in many healthy animals, e.g. avian species such as turkey and chicken, cattle, sheep, horses and rodents. Chicken meat, an important nutrient source in many countries world-wide is known to be very frequently contaminated with *Campylobacter* (Shane (1992), S.M., Avian Pathology 21: 189-213). This is not only the case in developing countries but also in e.g. Europe. *Campylobacter* resides in the gut of poultry. Contamination of the meat frequently happens in the slaughterhouse when the intestinal tract, which is often heavily *Campylobacter*-contaminated, is removed from the animal. Contamination during slaughter is very difficult to avoid. In the Netherlands, about 50 % of the chicken meat is contaminated, in spite of the high hygienic standards applied in meat industry. A recent overview of the Epidemiology of *Campylobacter* in poultry is given in the Thesis of C.M. Karssen, (ISBN 90-71463-72-9). As a result of this high contamination pressure, about 300,000 persons annually in the Netherlands only (total population 15.000.000) suffer from *Campylobacter* infection, caused by handling or eating undercooked poultry meat. These figures are not significantly different in other European countries. World-wide, annually more than 400.000.000 cases are estimated to occur (Pace et al., Vaccine 1998, 16: 1563-1574). *Campylobacter* causes enteric infections in humans, and occasionally more severe diseases like abortion, meningitis, appendicitis, and urinary tract infection. (Blaser et al., New Engl. J. Med. 1981, 305: 1444-1452, Butzler et al., Clinics in Gastroenterol. 1979, 8: 737-765). Also, severe neurologic complications such as Guillain-Barré syndrome and Miller-Fisher syndrome are sometimes seen (Schwerer et al., 1995, J. Endotox. Res. 2: 395-403 and Salloway et al., 1996, Infect. Immun. 64: 2945-2949). Diarrhoea due to *Campylobacter jejuni* is usually a self-limiting infection, lasting about 2-7 days. In young children, old people and immunocompromised patients, the disease is not self-limiting and requires antibiotic treatment.



It is clear that, if a potential vaccine against *Campylobacter* for human use would be available, it could prevent humans from becoming infected. This would however require a standard vaccination comparable to vaccination against e.g. mumps and measles. This is evidently not practical. A more logical approach lies in avoiding the transmission from animal to man, specifically from poultry to man. The easiest way of doing this is by vaccinating poultry against *Campylobacter* infection. Vaccination of poultry (as well as human vaccination) has however turned out to be much more complicated than was initially expected. This is due to the fact that *Campylobacter* is, in spite of the fact that it colonises the gut, not pathogenic to poultry. Most vaccines tested are inactivated whole cell preparations, administered systemically or orally, sometimes in combination with adjuvants. In some cases colonisation of the gut could, to a certain extent, be decreased, but there are no examples of vaccines avoiding colonisation. Shedding of *Campylobacter* could not be stopped by any of these vaccines. Killed whole cell vaccines, if compared with subunit vaccines, have been considered the best candidates for a vaccine, because in principle they still possess all potential immunogenic determinants. Next to the development of whole cell vaccines, much effort has been put in the development of flagella-based subunit vaccines. Flagella have been recognised as the immunodominant antigen recognised during infection and numerous studies have suggested a role for this protein in protection (Martin et al., Inf. And Immun. 1989, 57: 2542-2546, Wenman et al., J. Clin. Microbiol. 1985, 21: 108-112). Flagella-less mutants are known not to colonise the gut, and they disappear from the infected animal within one or two weeks whereas the wild type bacterium remains present in the gut. Flagella are thus by far the most likely candidates for the preparation of a vaccine, especially since they seem to play a key role, if not the only role, in the colonisation of the gut. If colonisation could be prevented, that would be a first step in the elimination of contamination in poultry. Nevertheless, potential vaccines based upon the flagella of *Campylobacter* have not given an acceptable level of protection.

Next to active vaccination as described above, passive vaccination has been tested as a means of decreasing *Campylobacter* infection. Tsubokura et al (1997, Clin. Exp. Immunol. 108: 451-455) have orally administered antibodies against whole *Campylobacter jejuni* cells followed by challenge with *Campylobacter jejuni*. They claim a 1-2 log reduction in the number of bacteria found in the faeces of thus vaccinated chickens.

All efforts made so far have not yet led to any vaccine, be it live, inactivated or on the basis of subunits, that is capable of significantly diminishing the level of colonisation and the amount of bacteria shedded in the faeces. It is clear, that there still is a need for a reliable and safe vaccine or alternative treatment.

In principle, there is no need to protect poultry against *Campylobacter* infection during their whole life span. They do not suffer from infection as explained above. Therefore, a treatment capable of diminishing the amount of bacteria and thus the infective pressure shortly before slaughter would be an efficient treatment for suppressing subsequent contamination of the meat during slaughter. And this in turn would prevent meat-transmitted human *Campylobacter* infection.

It is an objective of the present invention to provide a vaccine that is capable of both diminishing the level of colonisation and shedding, or even of eliminating *Campylobacter* from the caecum of poultry. This avoids *Campylobacter*-contamination of the meat during slaughtering and therefore avoids subsequent infection of humans.

It was surprisingly found now that a vaccine having these characteristics can be based upon antibodies against flagella-less mutants of *Campylobacter*. This is highly unexpected since, as mentioned above, flagella are considered to be the key protein involved in adherence and colonisation. Even more surprising, such a vaccine does diminish colonisation and shedding of wild type flagellated *Campylobacter*. This is the first time that a vaccine is reported that is even capable to eliminate *Campylobacter* from the ceca below the level of detection.

Thus, one embodiment of the invention relates to vaccines for the prevention of *Campylobacter* colonisation in animals, which vaccines comprise antiserum against a flagellaless *Campylobacter* strain.

Such a vaccine can in a very simple form comprise just isolated antiserum against *Campylobacter* and possibly a diluent. Such a diluent can be added to dilute the antiserum if the amount of antibody titre is too high. The diluent can be as simple as distilled water, or physiological salt solution. Actually any pharmaceutically acceptable diluent can be used.

The invention is equally applicable for *Campylobacter* contamination in poultry, pigs and other animals.

Given however the very high contamination pressure of chicken meat, a preferred form of this embodiment relates to flagellaless *Campylobacter* strains of the species *Campylobacter jejuni*, and to poultry.

Any flagella-less *Campylobacter* strain can be used for raising antiserum. Especially those flagella-less *Campylobacter* strains that have growth-rates comparable to wild type strains are preferred. A very suitable flagella-less *Campylobacter* strain for raising antibodies has been described by Wassenaar, T.M., Bleumink-Pluym, N.M.C. and van der Zeijst, B.A.M. 1991, in the EMBO Journal 10:2055-2061.

Thus, in a preferred form, the flagella-less *Campylobacter jejuni* strain against which the antibodies are raised, is strain R2.

Antibodies suitable for use in a vaccine according to the present invention can be obtained from polyclonal sera, monospecific sera or from monoclonal antibody culture. Polyclonal sera have the advantage that they are easily made according to standard techniques. Techniques for producing and processing polyclonal sera are abundantly known in the art (e.g. Mayer and Walter, eds. Immunochemical Methods in Cell and Molecular Biology, Academic Press, London, 1987). Animals suitable for raising the antibodies are e.g. cows, rabbits, mice and chickens. Efficient methods for obtaining bovine antibodies against *Campylobacter* are described by Hilpert et al., 1987, J. Inf. Diseases 156: 158-166. Another attractive way of producing large amounts of antibodies i.e. production in egg yolk has been described by Hatta et al., 1993, Biosci. Biotech. Biochem. 57: 450-454.

Another embodiment of the present invention relates to the use of antibodies against a flagella-less *Campylobacter jejuni* strain for the preparation of a vaccine against *Campylobacter jejuni* colonisation.

Even more surprisingly, the following was found: antiserum raised against flagellaless *Campylobacter jejuni* mutants recognises three major protein bands, a 97 kD (+/- 5 kD), a 60 kD (+/- 5 kD) band and a 13 kD (+/- 3 kD) band, on a Western blot of total *Campylobacter jejuni* protein, that are not seen when using antiserum against wild type *Campylobacter jejuni*. This phenomenon is equally seen in Western blots of wild type *Campylobacter* and of flagellaless *Campylobacter*. Thus, the three proteins are equally present in wild type and flagellaless *Campylobacter* strains. It was therefore concluded that the recognition of these specific proteins by the immune system only occurs on the absence of the flagella.

- As mentioned above, antiserum against flagellaless *Campylobacter* mutants is capable of eliminating *Campylobacter* from the ceca below the level of detection. This antiserum differs from antiserum against wild type *Campylobacter* (not capable of eliminating *Campylobacter*) in that it additionally comprises antibodies against the 97 kD, 60 kD and 13 kD proteins. These three proteins apparently only induce antibodies if the flagella is absent, so it was concluded that these three proteins are capable of inducing antibodies that play an essential role in the elimination of *Campylobacter* from the ceca. Therefore, antibodies raised against either the 97 kD, the 60 kD or the 13 kD protein or a combination thereof are equally capable of eliminating *Campylobacter* strains from the ceca.

- Thus another embodiment of the invention relates to antigenic proteins having a molecular weight of 97 kD, 60 kD or 13 kD, that are visible in a Western blot of *Campylobacter jejuni* protein after incubation of that Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that are not visible after incubation of that blot with antibodies against wild type *Campylobacter jejuni*.

The 60 kD protein and the 13 kD protein have been further analysed and their amino acid sequence has been determined.

- The amino acid sequence of the 60 kD protein is given below, and is also depicted in SEQ ID NO 1.

The amino acid sequence of the 60 kD protein is: "MAKEIIFSDEARNK-  
LYEGVKKLNDVAVKVTMGPRGRNVLIQKSFSGAPSITKDGVSVAKEVELKD-  
SLENMGASLVREVASKTADQAGDGTATTATVLAHAIFKEGLRNITAGANPIEVK-  
RGMKDACEAIVAEKKLSREVKDKKEIAQVATISANSDEKIGNLIADA-  
MEKVGKDGVIITVEEPKSIINDELNVVEGMQFDRGYLSPYFITNAEKMTVEL-  
SSPYILLFDDKITNLKDLLPVLEQIQKTGKPLIIAEDIEGEALATLVVNKLKRGV-  
LNIASVAKPGFGDRRKAMLEDIAILTTGGEVISEELGRTLESATIQDLGQASS-  
VIIDKDNITTVINGAGEKANIDARVNVQIKAQIAETTSYDREKLQERLAKLSG-  
GVAVIKVGATTETEMKEKKDRVDDALSATKAAVEEGIVIGGGAALIKAK-  
KAKIKLDLQGDGAIGAIAVERALRAPLRQAENAGFDAGVVVNSVENAK-  
DENTGFDAAKGEYVNNMLESGLIDPVKVERVALLNAVSVASMLLT-  
TEATISEIKEDKPTMPDMSGMGMGMGMGMGM"

- The amino acid sequence of the 13 kD protein is given below and in SEQ ID NO 2. The amino acid sequence of this protein is: "MAISKEDVLEYISNLSVLELSELVKE-

FEKFGVSAAPVMVAGGAVAGGAVAAAEKTEFDIVLTDGGAKKIEVI-  
KIVRALTLGLKEAKDAVEQTPSTLKEGVAKAEAEAKKQLEEAGAKVELK"

There may be slight modifications in the amino acid sequence of the 60 kD and 13 kD protein. Variation in amino acid sequence may be the result of replacement of one or more amino acids by functional equivalents. Replacement by functional equivalents is often seen. Examples described by Neurath et al (The Proteins, Academic Press, New York (1979), page 14, figure 6) are i.a. the replacement of the amino acid alanine by serine; Ala/Ser, or Val/Ile, Asp/Glu, etc. In addition to the variations leading to replacement by functional equivalent amino acids mentioned above, variations may be found, in which an amino acid has been replaced by another amino acid that is not a functional equivalent. This kind of variation only differs from replacement with functional equivalents in that it may yield a protein that has a slight modification in its spatial folding. Both types of variation are often seen in proteins, and they are known as biological variations.

It goes without saying, that variations in the amino acid sequence of the 60 kD and 13 kD protein in such a way that the immunogenic activity of the polypeptide is retained, are also within the scope of the present invention.

The 97 kD, 60 kD or 13 kD proteins can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). The 97 kD, 60 kD and 13 kD protein can be isolated according to many standard protein isolation procedures well-known in the art. One very easy method is the excision of these proteins from a preparative gel. If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are known in the art (e.g. Mayer and Walter, eds., see above). Monoclonal antibodies, reactive against the 97 kD, 60 kD or 13 kD proteins according to the invention (or variants or fragments thereof), can be prepared by immunising inbred mice by techniques known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

One of the advantages of using antibodies against any of these three proteins instead of antiserum against the whole flagellaless *Campylobacter* is, that specific monoclonal antibodies against these three proteins can easily be obtained from large scale hybridoma growth in fermentors. This allows the production of large amounts of antibodies at low costs/efforts and without the use of animals.

Thus, another embodiment of the invention relates to vaccines comprising antibodies against the 97 kD, 60 kD or 13 kD proteins of *Campylobacter*.

Even still another embodiment of the present invention relates to the use of antibodies against the 97 kD and/or 60 kD and/or 13 kD protein according to the invention for the preparation of a vaccine against *Campylobacter jejuni* colonisation.

The methods for the preparation of a vaccine according to the invention need not be complex. In principle, it suffices to raise antibodies against a flagella-less mutant or against the 97 kD and/or 60 kD and/or 13 kD protein in e.g. an animal, followed by collecting the blood and isolating the antiserum according to standard techniques. Suit-

able animals for raising such antibodies are e.g. rabbits and chickens. When chickens are used, antibodies can alternatively be obtained from the egg yolk of systemically immunised chickens. In principle the antibodies need not be diluted. They can be given as such, or if necessary even in a concentrated form. Alternatively, if the antibody concentration is very high, the thus obtained antiserum can e.g. be diluted before administration.

Thus, another embodiment of the present invention relates to methods for the preparation of a vaccine according to the invention. Such methods comprise raising antibodies against antigenic material of a flagellaless *Campylobacter jejuni* strain in a host animal followed by isolating the antibodies. In principle, this method will usually comprise the taking of blood from the host animal followed by purifying the antiserum, e.g. by centrifugation or filtration.

It is also possible to obtain cells that produce the desired antibodies, directed against the 97 kD, 60 kD and 13 kD proteins and to grow these in e.g. a fermentor. Antibodies can be harvested afterwards and they can be mixed, if necessary, with a pharmaceutically acceptable carrier. The advantage of such a method is that no animals need to be used for the preparation of the antibodies.

The invention is i.a. very suitable for treating broiler chicken, before slaughtering. Such broilers are usually slaughtered at six weeks of age. Therefore, treatment of the animals with the vaccine according to the invention at about one week before they are slaughtered causes a significant decrease in the level of *Campylobacter*-contamination. It is clear that the amount of vaccine to be given depends highly on the concentration of antibodies in the vaccine. As an indication may serve that very suitable amounts of antibodies are present in between 0.1 and 1 ml of crude antiserum.

Antibody-titres in e.g. egg-yolk preparations can easily be determined by standard techniques well-known in the art, such as the ELISA technique.

The antibodies can easily be given as a rather crude preparation. A possible way of administration is e.g. feeding crude antiserum to chickens. Alternative routes of administration are e.g. admixing the serum with drinking water. Also, antibodies can be mixed directly with chicken food. For such purposes, an alternative is freeze-drying of the antibodies, thus enhancing their long term stability, before mixing them with the food or water. Also, the antibodies can be encapsulated before adding them to chicken food.

Still another embodiment of the invention provides an alternative for using antiserum or antibodies according to the invention for vaccination purposes. Alternatively, it is possible to use the 97 kD, 60 kD or 13 kD protein according to the invention directly for vaccination purposes. When the 97 kD, 60 kD or 13 kD protein are administered directly to poultry, they induce antibodies against the 97 kD, 60 kD or 13 kD protein directly. The animals then produce their own protective antibodies against *Campylobacter*. Again, this is surprising: administration of whole wild type *Campylobacter* strains does not lead to elimination of *Campylobacter* from the ceca, because wild type *Campylobacter* strains suppress the induction of antibodies against the 97 kD, 60 kD and 13 kD pro-

teins. Thus, when the 97 kD, 60 kD and 13 kD protein are not given in an isolated form, but as a part of the whole wild type *Campylobacter* cell, they have no effect.

Thus, another embodiment relates to vaccines comprising the specific antigenic 97 kD, 60 kD or 13 kD protein that is visible in a Western blot of *Campylobacter jejuni* protein after incubation of that Western blot with antibodies against a flagellless mutant of *Campylobacter jejuni* and that is not visible after incubation of that blot with antibodies against wild type *Campylobacter jejuni*.

Such a vaccine can easily be prepared by admixing the protein with a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is understood to be a compound that does not adversely effect the health of the animal to be vaccinated, at least not to the extent that the adverse effect is worse than the effects seen when the animal is not vaccinated. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form, the carrier can e.g. be a buffer.

Still another embodiment of the present invention relates to the antigenic 97 kD, 60 kD or 13 kD protein according to the invention for use in a vaccine.

A preferred form of this embodiment relates to the use of the antigenic 97 kD, 60 kD or 13 kD protein according to the invention for the manufacturing of a pharmaceutical composition for combating *Campylobacter jejuni* colonisation.

Suitable amounts of protein for the preparation of vaccines vary according to the way of administration. For systemic application, amounts between 1 and 1000 µg are very suitable. In vaccines for oral administration the amount may also be in this range. If however oral vaccination through drinking water is envisaged, possibly larger amounts of protein have to be given, due to spillage of water.

The vaccine according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants are Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers and polyamines such as dextran sulphate, carboxypol and pyran. Also very suitable are surface active substances such as Span, Tween, hexadecylamine, lysolecithin, methoxyhexadecylglycerol and saponins (i.a. Quil A<sup>(R)</sup>). Furthermore, peptides such as muramyl dipeptides, dimethylglycine, tuftsin, are often used. Next to these adjuvants, Immune-stimulating Complexes (ISCOMS), mineral oil e.g. Bayol<sup>(R)</sup> or Markol<sup>(R)</sup>, vegetable oils or emulsions thereof and Diluvac<sup>(R)</sup> Forte can advantageously be used. The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle compounds are e.g. aluminium hydroxide, -phosphate, sulphate or -oxide, silica, Kaolin, and Bentonite. A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380).

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-

drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology 59: 509 (1950)), skimmed milk, gelatin, bovine serum albumin, carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

- 5 Freeze-drying is an efficient method for conservation. Freeze-dried material can be stored stable for many years. Storage temperatures for freeze-dried material may well be above zero degrees, without being detrimental to the material. Freeze-drying can be done according to all well-known standard freeze-drying procedures.

- 10 Vaccines comprising the 97 kD, 60 kD or 13 kD protein are preferably administered mucosally. This can e.g. be done by oral administration, through admixing of the vaccine with drinking water. Especially for poultry, additional methods such as intra-ocular vaccination and intranasal vaccination are also very suitable ways of mucosal vaccination.

## EXAMPLES

- 20 **Example 1: detection of a 97 kD, a 60 kD and a 13 kD protein.**

### Bacterial strains:

- Wild type 81116:** *Campylobacter jejuni*, wild type, human isolate, flagellum phenotype A<sup>+</sup>B<sup>+</sup>, motile and invasive in vitro (Wassenaar, T.M., Bleumink-Pluym, N.M.C. and van der Zeijst, B.A.M. 1991, EMBO Journal 10:2055-2061).

- 25 **Mutant 81116-R2:** FlaA and flaB deletion mutant (+kanamycin insert), flagellum phenotype A<sup>+</sup>B<sup>+</sup>, not motile and not invasive in vitro (Wassenaar, T.M., Bleumink-Pluym, N.M.C. and van der Zeijst, B.A.M. 1991, EMBO Journal 10:2055-2061).

- 30 **Cell growth:** Strain *Campylobacter jejuni* 81116 was inoculated on Blaser Campylobacter agar and strain *Campylobacter jejuni* 81116-R2 was inoculated on Blaser Campylobacter agar + 40 µg/ml kanamycin. Plates were incubated for 48 hours at 41 degrees C under microaerophilic conditions. A small number of colonies from the agar plates were inoculated in Brucella broth + 1% yeast extract for strain 81116 and in Brucella broth + 1% yeast extract + 40 µg/ml kanamycin for strain 81116-2R. After incubation for 24 hours at 41 degrees C under microaerophilic conditions, cultures were checked for the total number of bacteria and 0.2% formalin was added for inactivation (room temperature for 24 hours). Inactivated bacteria were collected by centrifugation.
- 35 Cell pellets were resuspended in 0.01 M Tris pH 7.4 to a protein concentration of 1.0 mg/ml.
- 40

Then for standard PAAGE, 20 µl of this suspension was added per slot and run, on NuPage gel 4-12% Bis-Tris. Western blotting was done with NuPage transfer buffer/10% methanol.

For 2-D gel electrophoresis, standard methods as described by Adessi, C. (Electrophoresis 1997, 18 127-135) and by Görg, A., (Electrophoresis 1995, 16, 1079-1086) and the Instruction Manual 18-1038-63 of Pharmacia were used.

5 Preparation of chicken antisera.

4-Weeks-old chickens were IM vaccinated with 1 ml whole cell vaccine (see below) of strain 81116 or 81116-R2. One group of chickens was left unvaccinated. At 4 weeks after vaccination all chickens were bled to death. Sera were pooled per group and used for immunisation of 4-days-old chickens.

10

Sera thus obtained were diluted 20, 200 or 400 times and incubated with the Western blot according to standard methods.

15 **Results:** The left Western blot of figure 1 comprises total antigen of wild type *Campylobacter* strain 81116, the right Western blot comprises antigen of flagellaless *Campylobacter* strain 81116-2R. Lanes 1 and 7, lanes 2 and 8, and lanes 3 and 9 were incubated with 20, 200 or 400 times diluted antiserum against wild type *Campylobacter* strain 81116 respectively. Lanes 4 and 10, lanes 5 and 11, and lanes 6 and 12 were incubated with 20, 200 or 400 times diluted antiserum against flagellaless *Campylobacter* strain 81116-2R respectively.

20

As can be clearly seen in lanes 4-6 and lanes 10-12, two bands are visible with molecular weights of 97 and 60 kD respectively, that are not visible in lanes 1-3 and 7-9. (the somewhat fainter and more diffuse bands in between these lanes are molecular weight markers).

25

Figure 2 shows a 2-D gel comprising total antigen of wild type *Campylobacter* strain 81116. A 2-D gel is better suitable for the detection of smaller proteins, and therefore, it is more suitable than standard 1-D PAGE for detecting the presence of (antibodies against) the 13 kD protein. Figure 3 shows Western blots of this gel. Blotting/incubation procedures were standard procedures comparable to those used for figure 1. Figure 3a shows a Western blot of the 2-D gel incubated with antiserum against flagellaless *Campylobacter* strain 81116-2R. Figure 3b shows the same Western blot, now incubated with antiserum against wild-type *Campylobacter* strain 81116. The Western blot in figure 3a clearly shows the presence of the antibodies against the 60 kD (arrow 1) and 13 kD protein (arrow 2) in serum raised against the flagellaless *Campylobacter*, and not found in serum raised against the wild-type *Campylobacter* (Fig. 3b).

30

35

These Western blots clearly show that flagellaless *Campylobacter* strains are capable of inducing an immune response against a 97 kD, a 60 kD and a 13 kD protein, whereas wild type *Campylobacter* strains do not show this phenomenon.

40

**Example 2: preparation of vaccines.**

45 Bacterial strains:

**Wild type 81116:** see above.



**Mutant 81116-R2:** see above.

Preparation of chicken antisera for passive immunisation.

- 4-Weeks-old chickens were IM vaccinated with 1 ml whole cell vaccine (see below) of strain 81116 or 81116-R2. One group of chickens was left unvaccinated. At 4 weeks after vaccination all chickens were bled to death. Sera were pooled per group and used for immunisation of 4-days-old chickens.

Preparation of inactivated whole cell vaccines.

- Strain *Campylobacter jejuni* 81116 was inoculated on Blaser *Campylobacter* agar and strain *Campylobacter jejuni* 81116-R2 was inoculated on Blaser *Campylobacter* agar + 40 µg/ml kanamycin. Plates were incubated for 48 hours at 41°C under microaerophilic conditions. Colonies from the agar plates were inoculated in Brucella broth + 1% yeast extract for strain 81116 and in Brucella broth + 1% yeast extract + 40 µg/ml kanamycin for strain R2. After incubation for 24 hours at 41°C under microaerophilic conditions, cultures were checked for the total number of bacteria and 0.2% formalin was added for inactivation (room temperature during 24 hours). Inactivated bacteria were collected by centrifugation, suspended in PBS and used for vaccine preparation by mixing cells and a Freund's incomplete type of water in oil emulsion. The vaccine emulsions contain approximately  $10^9$  bacteria per ml.

Preparation of *Campylobacter* challenge strain.

- Strain *Campylobacter jejuni* 81116 was grown on Blaser *Campylobacter* agar plates at 41°C for 48 hours under microaerophilic conditions. The growth of one plate was suspended in Brucella broth + 1% Yeast extract and incubated at 41°C for 48 hours in a closed bottle. Chickens were challenged orally with 0.2 ml culture. Viability count of the challenge culture was determined by plate counting.

**Example 3: vaccination experiments.**

In this experiment, a comparison is made between passive vaccination with antiserum against wild type *Campylobacter* and against flagella-less *Campylobacter*, and active vaccination with an inactivated wild type *Campylobacter* whole cell preparation.

**Chickens**

Four-days-old or two-weeks-old SPF chickens.

Experimental design experiment 1.

- Four groups of ten 4-days-old chickens were (once daily) treated orally with 0.8 ml chicken antiserum to wild type *Campylobacter* strain 81116, or with 0.8 ml chicken antiserum to the flagellaless mutant 81116-R2 or with 0.8 ml unvaccinated control chicken serum, or were left untreated as control. The first day (i.e. at 4-days of age) chicken received antisera just before challenge with  $3.2 \times 10^7$  CFU/ml, as well as 6 hours after challenge. Treatments were continued until necropsy. At 5 or 10 days after challenge 5 birds of each group were killed and the CFU per gram cecal content was determined (see below: Post-mortem and bacteriology).

### Experimental design experiment 2.

Four groups of ten 4-days-old chickens were (once daily) treated orally with 0.8 ml chicken antiserum to wild type *Campylobacter* strain 81116, or with chicken antiserum to the flagellaless mutant strain 81116-R2 or with unvaccinated control chicken serum or were left untreated. The first day (i.e. at 4 days of age) antisera were given just before challenge with  $1.4 \times 10^8$  CFU/ml, as well as 6 hours after challenge. Treatments were continued until necropsy. At 5 days after challenge the chickens were killed and the CFU per gram cecal content was determined.

### Experimental design experiment 3.

Three groups of 10 two-weeks-old chickens were vaccinated IM with 1 ml of the whole cell vaccines in a Freund's Incomplete type of water in oil emulsion, containing inactivated cells of wild type *Campylobacter* strain 81116 or the flagellaless mutant strain 81116-R2 or were left unvaccinated. At 5 weeks of age all chickens were challenged orally with wild type *Campylobacter* strain 81116,  $1.4 \times 10^8$  CFU/ml. One week after challenge the chickens were killed and the CFU per gram cecal content was determined.

### Post-mortem and Bacteriology

Chickens were killed and the content of each caecum was gently removed, weighed and diluted to 0.1 g per ml in 0.04 M PBS. Serial 10-fold dilutions were then plated out on selective Blaser *Campylobacter* agar plates. After 48 hours of incubation at 41°C under microaerophilic conditions, the CFU per gram cecal content was determined.

## **RESULTS**

### Experiment 1

From Table 1 it can be concluded that repeated daily passive immunisation with serum against wild type *Campylobacter* or with unvaccinated chicken control serum had no effect on cecal colonisation by wild type *Campylobacter* if compared to untreated control chickens (at 5 days as well as 10 days after challenge). All three groups showed high levels of cecal colonisation by *Campylobacter* (up to  $> 10^8$  CFU per gram cecal content). In sharp contrast, passive immunisation with antiserum according to the invention (i.e. raised against a flagella-negative mutant) resulted in elimination of wild type *Campylobacter* from the ceca (or prevented colonisation). A level of  $< 3$  means that the number of CFU / gram caecum content is below the level of detection.

### Experiment 2

In this experiment testing was repeated (see Table 2). Again a strong reduction of cecal colonisation was found in chickens passively vaccinated with antiserum according to the invention (i.e. raised against a flagella-negative mutant): 6/10 chickens were completely negative and a mean reduction of  $> 3$  logs was found.

### Experiment 3

Because literature indicated that active immunisation with wild type *Campylobacter* could result in maximally 2 logs reduction of *Campylobacter* colonisation (Widders, P.R., Perry, R., Muir, W.I., Husband, A.J. and Long, K.A., 1996, Br. Poultry Sci. 37:765-778.), we tested and compared wild type and R2 based vaccines in an active protection model.

5

From the results (Table 3) it is clear that neither vaccine had an effect on cecal colonisation.

10

09544583-040700

**Reisolation of *C. jejuni* 81116, 5 days after challenge**

	Log CFU/gram caecum content			
Antiserum	<i>C. jejuni</i> 81116	<i>C. jejuni</i> R2	Not vaccinated	No antiserum
Chicken				
1	8.1	<3.0	7.8	7.6
2	5.9	<3.0	8.7	5.6
3	8.5	<3.0	8.1	9.1
4	5.5	<3.0	7.7	7.2
5	8.6	<3.0	7.6	8.8
<b>Mean</b>	<b>7.3</b>	<b>&lt;3.0</b>	<b>8.0</b>	<b>7.7</b>
<b>Sd</b>	<b>1.5</b>		<b>0.4</b>	<b>1.4</b>

Table 1a.

**Reisolation of *C. jejuni* 81116, 10 days after challenge**

	Log CFU/gram caecum content			
Antiserum	<i>C. jejuni</i> 81116	<i>C. jejuni</i> R2	Not vaccinated	No antiserum
Chicken				
1	9.0	3.5	7.8	8.1
2	9.1	<3.0	8.9	7.6
3	9.0	<3.0	9.3	7.4
4	9.1	<3.0	7.0	7.8
5	8.5	<3.0	8.7	8.2
<b>Mean</b>	<b>8.9</b>	<b>&lt;3.1</b>	<b>8.3</b>	<b>7.8</b>
<b>Sd</b>	<b>0.3</b>	<b>0.2</b>	<b>0.9</b>	<b>0.3</b>

5 Table 1b.

Reisolation of *C. jejuni* 81116, 5 days after challenge

		Log CFU / gram caecum content		
Antiserum	<i>C. jejuni</i> 81116	<i>C. jejuni</i> R2	Not vaccinated	No antiserum
Chicken				
1	7.5	3.8	9.5	<3.0
2	<3.0	9.1	7.9	7.5
3	7.4	8.9	7.6	7.9
4	7.5	6.0	8.4	8.5
5	6.0	<3.0	7.3	9.0
6	9.1	<3.0	7.0	5.8
7	8.9	<3.0	6.6	9.0
8	7.6	<3.0	9.1	7.0
9	<3.0	<3.0	7.5	9.0
10	<3.0	<3.0	9.4	9.8
Mean	<6.3 <sup>a</sup>	<4.6 <sup>b</sup>	8.0	<7.7
Sd	2.4	2.5	1.0	2.0

Table 2.

<sup>a</sup>  $p \leq 0.05$  compared to the group receiving antiserum of not vaccinated chickens (two sample t-tests)

<sup>b</sup>  $p \leq 0.001$  compared to the group receiving antiserum of not vaccinated chickens (two sample t-tests)

**Reisolation of *C. jejuni* 81116, 6 days after challenge.**

Chicken	Log CFU / gram caecum content		
	Vaccination with <i>C. jejuni</i> 81116	Vaccination with <i>C. jejuni</i> R2	Not vaccinated
1	8.3	5.2	8.3
2	8.7	8.0	8.7
3		8.7	
4	7.1	8.5	7.1
5	8.1	7.8	8.1
6	8.4		8.4
7	7.7	7.8	7.7
8	8.5	8.8	8.5
9	9.1	8.3	9.1
10	7.5	7.4	7.5
<b>Mean</b>	<b>8.2</b>	<b>7.8</b>	<b>8.2</b>
<b>Std.</b>	<b>0.6</b>	<b>1.1</b>	<b>0.6</b>

Table 3.

**Conclusion:**

Vaccines based upon antibodies raised against flagella-less *Campylobacter* are capable of eliminating wild-type *Campylobacter* from the caecum. This is in sharp contrast to their counterparts having antibodies raised against wild type *Campylobacter*. It is also in sharp contrast to vaccines comprising wild type *Campylobacter* cells.

09544533.040700

# Legend to the figures

Figure 1. Western blot comprising total antigen of wild type *Campylobacter* strain 81116 (left), and Western blot comprising antigen of flagellaless *Campylobacter* strain 81116-2R. Lanes 1 and 7, lanes 2 and 8, and lanes 3 and 9 were incubated with 20, 200 or 400 times diluted antiserum against wild type *Campylobacter* strain 81116 respectively. Lanes 4 and 10, lanes 5 and 11, and lanes 6 and 12 were incubated with 20, 200 or 400 times diluted antiserum against flagellaless *Campylobacter* strain 81116-2R respectively.

Figure 2. 2-D gel of total antigen of wild type *Campylobacter* strain 81116.

Figure 3a. Western blot of the 2-D gel incubated with antiserum against flagellaless *Campylobacter* strain 81116-2R. The 60 kD protein is indicated by arrow 1, the 13 kD protein by arrow 2.

Figure 3b. Western blot incubated with antiserum against wild-type *Campylobacter* strain 81116.

09544587:040700

### Claims

- 1) Vaccine for the prevention of *Campylobacter* colonisation in animals, characterised in that said vaccine comprises antiserum raised against a flagellaless *Campylobacter* strain.
- 2) Vaccine according to claim 1, characterised in that the flagellaless *Campylobacter* strain is *Campylobacter jejuni*.
- 3) Vaccine according to claim 2, characterised in that the flagellaless *Campylobacter jejuni* strain is strain R2.
- 4) Antigenic protein of *Campylobacter* having a molecular weight of 97 kD (+/- 5 kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.
- 5) Antigenic protein of *Campylobacter* having a molecular weight of 60 kD (+/- 5 kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.
- 6) Antigenic protein of *Campylobacter* having a molecular weight of 13 kD (+/- 3 kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.
- 7) Antigenic protein according to claim 4, 5 or 6 for use in a vaccine.
- 8) Use of antigenic protein as defined in claim 4, 5 or 6 for the manufacturing of a pharmaceutical composition for combating *Campylobacter jejuni* colonisation.
- 9) Vaccine for the prevention of *Campylobacter jejuni* colonisation in poultry, characterised in that said vaccine comprises antibodies against the antigenic protein according to claim 4, 5 or 6.
- 10) Vaccine for the prevention of *Campylobacter jejuni* colonisation in poultry, characterised in that said vaccine comprises an antigenic protein according to claim 4, 5 or 6.
- 11) Use of antibodies against a flagellaless *Campylobacter* strain, or against the antigenic protein of claim 4, 5 or 6 for the preparation of a vaccine against *Campylobacter* colonisation in animals.



12) Method for the preparation of a vaccine according to any of the claims 1-3 or 9, characterised in that said method comprises raising antiserum against antigenic material of a flagellaless *Campylobacter* strain in a host animal followed by isolating the antiserum from the host animal.

13) Method for the preparation of a vaccine according to claim 9, characterised in that said method comprises growing antibody producing cells and harvesting the antibodies.

14) Method for the preparation of a vaccine according to claim 10, characterised in that said method comprises admixing a protein according to any of the claims 4-6 and a pharmaceutically acceptable carrier.

002010-23-04250

### Abstract

The present invention relates to vaccines comprising antiserum raised against a flagellaless *Campylobacter* strain for the prevention of *Campylobacter* colonisation in animals. The invention also relates to antigenic *Campylobacter* proteins visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such *Campylobacter* proteins and to antiserum and antibodies raised against *Campylobacter* antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines.

0344562.040706



### Figure 1




Figure 2

Anti-R2 antisera




Figure 3a

Anti-81116 sera



Figure 3b

00544683 040700

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled:

**"CAMPYLOBACTER VACCINE"**

the specification of which

[CHECK ONE]

☒ is attached hereto

☐ was filed on \_\_\_\_\_ as Application Serial No.

\_\_\_\_\_ and was amended on \_\_\_\_\_

[if applicable]

☐ was filed under the Patent Cooperation Treaty on

Serial \_\_\_\_\_ The United States of America being designated.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority claimed
<u>99201086.8</u>	<u>EP</u>	<u>09 / 04 / 1999</u>	<u>X</u> Yes ___ No
Number	Country	Day/Month/Year filed	
_____	_____	/ /	___ Yes ___ No
Number	Country	Day/Month/Year filed	
_____	_____	/ /	___ Yes ___ No
Number	Country	Day/Month/Year filed	

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which

became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

(U.S. Serial No. (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, Mary E. Gormley, Registration No. 34,409, Gregory R. Muir, Registration No. 35,293 and Michael G. Sullivan, Registration No. 35,377.

Please address all communications to:

William M. Blackstone  
AKZO NOBEL  
1300 Piccard Drive #206  
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Antonius, Arnoldus, Christiaan JACOBS

Inventor's signature [Signature] March 28, 2000  
Date

Citizenship Dutch

Residence and P.O. Address Ondersteweg 2, 5995 PS KESSEL - The Netherlands

Full name of second joint inventor Johannes, Franciscus van den BOSCH

Inventor's signature [Signature] March 28, 2000  
Date

Citizenship Dutch

Residence and P.O. Address Spoorstraat 9, 5831 CH BOXMEER - The Netherlands

Full name of third joint inventor Petrus, Johannes, Maria NULTEN

Inventor's signature [Signature] March 28, 2000  
Date

Citizenship Dutch

Residence and P.O. Address De Linde 10, 5831 RD BOXMEER - The Netherlands

Full name of forth joint inventor \_\_\_\_\_

Inventor's signature \_\_\_\_\_  
Date

Citizenship \_\_\_\_\_

Residence and P.O. Address \_\_\_\_\_

## &lt;110&gt; AKZO Nobel N.V.

<120> Campylobacter vaccine

<130> campylotest

<140>

<141>

&lt;160&gt; 2

&lt;170&gt; PatentIn Ver. 2.1

<210> 1

<211> 125

&lt;212&gt; PRT

<213> Campylobacter jejuni

<400> 1

Met Ala Ile Ser Lys Glu Asp Val Leu Glu Tyr Ile Ser Asn Leu Ser  
1 5 10 15

Val Leu Glu Leu Ser Glu Leu Val Lys Glu Phe Glu Glu Lys Phe Gly  
20 25 30

Val Ser Ala Ala Pro Val Met Val Ala Gly Gly Ala Val Ala Gly Gly  
35 40 45

Ala Val Ala Ala Ala Glu Glu Lys Thr Glu Phe Asp Ile Val Leu Thr  
50 55 60

Asp Gly Gly Ala Lys Lys Ile Glu Val Ile Lys Ile Val Arg Ala Leu  
65 70 75 80

Thr Gly Leu Gly Leu Lys Glu Ala Lys Asp Ala Val Glu Gln Thr Pro  
85 90 95

Ser Thr Leu Lys Glu Gly Val Ala Lys Ala Glu Ala Glu Glu Ala Lys  
100 105 110

Lys Gln Leu Glu Glu Ala Gly Ala Lys Val Glu Leu Lys  
115 120 125

 $\langle 210 \rangle$  2

<211> 545

&lt;212&gt; PRT

<213> Campylobacter jejuni

<400> 2

Met Ala Lys Glu Ile Ile Phe Ser Asp Glu Ala Arg Asn Lys Leu Tyr  
1 5 10 15

Glu Gly Val Lys Lys Leu Asn Asp Ala Val Lys Val Thr Met Gly Pro  
20 25 30



Arg Gly Arg Asn Val Leu Ile Gln Lys Ser Phe Gly Ala Pro Ser Ile  
 35 40 45  
 Thr Lys Asp Gly Val Ser Val Ala Lys Glu Val Glu Leu Lys Asp Ser  
 50 55 60  
 Leu Glu Asn Met Gly Ala Ser Leu Val Arg Glu Val Ala Ser Lys Thr  
 65 70 75 80  
 Ala Asp Gln Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala His  
 85 90 95  
 Ala Ile Phe Lys Glu Gly Leu Arg Asn Ile Thr Ala Gly Ala Asn Pro  
 100 105 110  
 Ile Glu Val Lys Arg Gly Met Asp Lys Ala Cys Glu Ala Ile Val Ala  
 115 120 125  
 Glu Leu Lys Lys Leu Ser Arg Glu Val Lys Asp Lys Lys Glu Ile Ala  
 130 135 140  
 Gln Val Ala Thr Ile Ser Ala Asn Ser Asp Glu Lys Ile Gly Asn Leu  
 145 150 155 160  
 Ile Ala Asp Ala Met Glu Lys Val Gly Lys Asp Gly Val Ile Thr Val  
 165 170 175  
 Glu Glu Pro Lys Ser Ile Asn Asp Glu Leu Asn Val Val Glu Gly Met  
 180 185 190  
 Gln Phe Asp Arg Gly Tyr Leu Ser Pro Tyr Phe Ile Thr Asn Ala Glu  
 195 200 205  
 Lys Met Thr Val Glu Leu Ser Ser Pro Tyr Ile Leu Leu Phe Asp Lys  
 210 215 220  
 Lys Ile Thr Asn Leu Lys Asp Leu Leu Pro Val Leu Glu Gln Ile Gln  
 225 230 235 240  
 Lys Thr Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Ile Glu Gly Glu  
 245 250 255  
 Ala Leu Ala Thr Leu Val Val Asn Lys Leu Arg Gly Val Leu Asn Ile  
 260 265 270  
 Ser Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met Leu  
 275 280 285  
 Glu Asp Ile Ala Ile Leu Thr Gly Gly Glu Val Ile Ser Glu Glu Leu  
 290 295 300  
 Gly Arg Thr Leu Glu Ser Ala Thr Ile Gln Asp Leu Gly Gln Ala Ser  
 305 310 315 320  
 Ser Val Ile Ile Asp Lys Asp Asn Thr Thr Ile Val Asn Gly Ala Gly  
 325 330 335  
 Glu Lys Ala Asn Ile Asp Ala Arg Val Asn Gln Ile Lys Ala Gln Ile  
 340 345 350

00044333.000700

Ala Glu Thr Thr Ser Asp Tyr Asp Arg Glu Lys Leu Gln Glu Arg Leu  
355 360 365

Ala Lys Leu Ser Gly Gly Val Ala Val Ile Lys Val Gly Ala Thr Thr  
370 375 380

Glu Thr Glu Met Lys Glu Lys Lys Asp Arg Val Asp Asp Ala Leu Ser  
385 390 395 400

Ala Thr Lys Ala Ala Val Glu Glu Gly Ile Val Ile Gly Gly Gly Ala  
405 410 415

Ala Leu Ile Lys Ala Lys Ala Lys Ile Lys Leu Asp Leu Gln Gly Asp  
420 425 430

Glu Ala Ile Gly Ala Ala Ile Val Glu Arg Ala Leu Arg Ala Pro Leu  
435 440 445

Arg Gln Ile Ala Glu Asn Ala Gly Phe Asp Ala Gly Val Val Val Asn  
450 455 460

Ser Val Glu Asn Ala Lys Asp Glu Asn Thr Gly Phe Asp Ala Ala Lys  
465 470 475 480

Gly Glu Tyr Val Asn Met Leu Glu Ser Gly Ile Ile Asp Pro Val Lys  
485 490 495

Val Glu Arg Val Ala Leu Leu Asn Ala Val Ser Val Ala Ser Met Leu  
500 505 510

Leu Thr Thr Glu Ala Thr Ile Ser Glu Ile Lys Glu Asp Lys Pro Thr  
515 520 525

Met Pro Asp Met Ser Gly Met Gly Gly Met Gly Gly Met Gly Gly Met  
530 535 540

Met  
545

054433.040700



# SEQUENCE LISTING

<110> JACOBS, ANTONIUS A.C.  
VAN DEN BOSCH, JOHANNES F.  
NUITJEN, PETRUS J.M.

<120> CAMPYLOBACTER VACCINE

<130> JACOBS

<140> 09/TO BE ASSIGNED

<141> 2000-04-07

<150> EP99201086.8

<151> 1999-04-09

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 125

<212> PRT

<213> Campylobacter jejuni

<400> 1

Met	Ala	Ile	Ser	Lys	Glu	Asp	Val	Leu	Glu	Tyr	Ile	Ser	Asn	Leu	Ser
1				5					10					15	

Val	Leu	Glu	Leu	Ser	Glu	Leu	Val	Lys	Glu	Phe	Glu	Glu	Lys	Phe	Gly
			20					25					30		

Val	Ser	Ala	Ala	Pro	Val	Met	Val	Ala	Gly	Gly	Ala	Val	Ala	Gly	Gly
		35					40					45			

Ala	Val	Ala	Ala	Ala	Glu	Glu	Lys	Thr	Glu	Phe	Asp	Ile	Val	Leu	Thr
	50					55					60				

Asp	Gly	Gly	Ala	Lys	Lys	Ile	Glu	Val	Ile	Lys	Ile	Val	Arg	Ala	Leu
65					70					75				80	

Thr	Gly	Leu	Gly	Leu	Lys	Glu	Ala	Lys	Asp	Ala	Val	Glu	Gln	Thr	Pro
				85					90					95	

Ser	Thr	Leu	Lys	Glu	Gly	Val	Ala	Lys	Ala	Glu	Ala	Glu	Glu	Ala	Lys
			100						105					110	

Lys Gln Leu Glu Glu Ala Gly Ala Lys Val Glu Leu Lys

00544563 040700

115

120

125

&lt;210&gt; 2

&lt;211&gt; 545

&lt;212&gt; PRT

&lt;213&gt; Campylobacter jejuni

&lt;400&gt; 2

Met Ala Lys Glu Ile Ile Phe Ser Asp Glu Ala Arg Asn Lys Leu Tyr  
 1 5 10 15

Glu Gly Val Lys Lys Leu Asn Asp Ala Val Lys Val Thr Met Gly Pro  
 20 25 30

Arg Gly Arg Asn Val Leu Ile Gln Lys Ser Phe Gly Ala Pro Ser Ile  
 35 40 45

Thr Lys Asp Gly Val Ser Val Ala Lys Glu Val Glu Leu Lys Asp Ser  
 50 55 60

Leu Glu Asn Met Gly Ala Ser Leu Val Arg Glu Val Ala Ser Lys Thr  
 65 70 75 80

Ala Asp Gln Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala His  
 85 90 95

Ala Ile Phe Lys Glu Gly Leu Arg Asn Ile Thr Ala Gly Ala Asn Pro  
 100 105 110

Ile Glu Val Lys Arg Gly Met Asp Lys Ala Cys Glu Ala Ile Val Ala  
 115 120 125

Glu Leu Lys Lys Leu Ser Arg Glu Val Lys Asp Lys Lys Glu Ile Ala  
 130 135 140

Gln Val Ala Thr Ile Ser Ala Asn Ser Asp Glu Lys Ile Gly Asn Leu  
 145 150 155 160

Ile Ala Asp Ala Met Glu Lys Val Gly Lys Asp Gly Val Ile Thr Val  
 165 170 175

Glu Glu Pro Lys Ser Ile Asn Asp Glu Leu Asn Val Val Glu Gly Met  
 180 185 190

Gln Phe Asp Arg Gly Tyr Leu Ser Pro Tyr Phe Ile Thr Asn Ala Glu  
 195 200 205

Lys Met Thr Val Glu Leu Ser Ser Pro Tyr Ile Leu Leu Phe Asp Lys  
210 215 220

Lys Ile Thr Asn Leu Lys Asp Leu Leu Pro Val Leu Glu Gln Ile Gln  
225 230 235 240

Lys Thr Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Ile Glu Gly Glu  
245 250 255

Ala Leu Ala Thr Leu Val Val Asn Lys Leu Arg Gly Val Leu Asn Ile  
260 265 270

Ser Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met Leu  
275 280 285

Glu Asp Ile Ala Ile Leu Thr Gly Gly Glu Val Ile Ser Glu Glu Leu  
290 295 300

Gly Arg Thr Leu Glu Ser Ala Thr Ile Gln Asp Leu Gly Gln Ala Ser  
305 310 315 320

Ser Val Ile Ile Asp Lys Asp Asn Thr Thr Ile Val Asn Gly Ala Gly  
325 330 335

Glu Lys Ala Asn Ile Asp Ala Arg Val Asn Gln Ile Lys Ala Gln Ile  
340 345 350

Ala Glu Thr Thr Ser Asp Tyr Asp Arg Glu Lys Leu Gln Glu Arg Leu  
355 360 365

Ala Lys Leu Ser Gly Gly Val Ala Val Ile Lys Val Gly Ala Thr Thr  
370 375 380

Glu Thr Glu Met Lys Glu Lys Lys Asp Arg Val Asp Asp Ala Leu Ser  
385 390 395 400

Ala Thr Lys Ala Ala Val Glu Glu Gly Ile Val Ile Gly Gly Gly Ala  
405 410 415

Ala Leu Ile Lys Ala Lys Ala Lys Ile Lys Leu Asp Leu Gln Gly Asp  
420 425 430

Glu Ala Ile Gly Ala Ala Ile Val Glu Arg Ala Leu Arg Ala Pro Leu  
435 440 445

Arg Gln Ile Ala Glu Asn Ala Gly Phe Asp Ala Gly Val Val Val Asn  
450 455 460

Ser Val Glu Asn Ala Lys Asp Glu Asn Thr Gly Phe Asp Ala Ala Lys  
 465 470 475 480

Gly Glu Tyr Val Asn Met Leu Glu Ser Gly Ile Ile Asp Pro Val Lys  
 485 490 495

Val Glu Arg Val Ala Leu Leu Asn Ala Val Ser Val Ala Ser Met Leu  
 500 505 510

Leu Thr Thr Glu Ala Thr Ile Ser Glu Ile Lys Glu Asp Lys Pro Thr  
 515 520 525

Met Pro Asp Met Ser Gly Met Gly Gly Met Gly Gly Met Gly Gly Met  
 530 535 540

Met  
 545

000000-2894560